A5008310956- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Geotechnical Engineering and Analysis
- Monoclonal and Polyclonal Antibodies Research
- Geotechnical Engineering and Underground Structures
- Biosimilars and Bioanalytical Methods
- Concrete and Cement Materials Research
- Cancer-related molecular mechanisms research
- Histone Deacetylase Inhibitors Research
- Circular RNAs in diseases
- Gastric Cancer Management and Outcomes
- Cancer Genomics and Diagnostics
- Radiopharmaceutical Chemistry and Applications
- Climate change and permafrost
- MicroRNA in disease regulation
- Grouting, Rheology, and Soil Mechanics
- Cancer Immunotherapy and Biomarkers
- Soil, Finite Element Methods
- Lung Cancer Research Studies
- Cancer, Lipids, and Metabolism
- Nanoparticle-Based Drug Delivery
Tianjin Medical University Cancer Institute and Hospital
2015-2025
Hebei General Hospital
2025
Shaanxi University of Chinese Medicine
2025
Second Military Medical University
2025
Shanghai Tunnel Engineering (China)
2020-2024
National Clinical Research
2015-2024
Jiangsu Provincial Institute of Geological Survey
2022-2024
East China Mineral Exploration & Development Bureau
2023-2024
Shanghai Jiao Tong University
2024
Bureau of Geology and Mineral Exploration and Development of Guizhou Province
2023-2024
Small molecules that can selectively target cancer stem cells (CSCs) remain rare currently and exhibit no common structural features. Here we report a series of guaianolide sesquiterpene lactones (GSLs) their derivatives eradicate acute myelogenous leukemia (AML) or progenitor cells. Natural GSL compounds arglabin, an anticancer clinical drug, micheliolide (MCL), are able to reduce the proportion AML (CD34⁺CD38⁻) in primary Targeting is further confirmed by sharp reduction colony-forming...
Antibody–drug conjugate (ADC) product specifications identify gastrointestinal adverse reactions. Nevertheless, there is a scarcity of comparative studies pertaining to these side effects similar medications. Special attention warranted for drug reactions (ADRs) affecting the system that are inadequately documented in literature. Utilizing U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), data mining was conducted analyze associated with ADCs. This analysis...
Abstract Romidepsin (FK228), a histone deacetylase inhibitor (HDACi), has anti-tumor effects against several types of solid tumors. Studies have suggested that HDACi could upregulate PD-L1 expression in tumor cells and change the state immune responses vivo. However, influence enhanced induced by romidepsin on is still under debate. So, purpose this study was to explore colon cancer. The results indicated inhibited proliferation, G0/G1 cell cycle arrest increased apoptosis CT26 MC38 cells....
Aberrant expression of histone deacetylase 6 (HDAC6) is greatly involved in neoplasm metastasis, which a leading cause colon cancer related death. Thus, deep understanding the regulatory mechanisms HDAC6 metastasis warranted. In this study, we firstly found that was highly expressed metastatic tissues and inhibition or knockdown suppressed metastasis. Next, based on proteomic analysis uncovered A-kinase anchoring protein 12 (AKAP12) novel substrate HDAC6. interacted with AKAP12 deacetylated...
The objective of the study was to compare disease-free survival and overall in a group matched males females with breast cancer, analyze possible treatment- gender-related differences.We retrospectively analyzed data 150 operable male cancer patients treated our hospital from December 1980 June 2012. Each patient recorded database two female equal stage. Prognosis terms evaluated.The mean age at diagnosis 58.6 ± 9.7 years for 57.2 10.3 females. median follow-up 69 months 81 Significant...
Breast cancer is the most common malignant tumor in Chinese women. Early screening best way to improve rates of early diagnosis and survival breast patients. The peak onset age for women considerably younger than those European American It imperative develop guideline that suitable By summarizing current evidence on women, referring latest guidelines consensus Europe, United States, East Asia, China Anti-Cancer Association National Clinical Research Center Cancer (Tianjin Medical University...
Apatinib (YN968D1) is a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2). We conducted single-arm, nonrandomized phase II study (NCT03121846) to assess the efficacy and safety of apatinib in patients with stage IV sarcoma. recruited 64 sarcoma who had failed chemotherapy. The primary endpoint was progression-free survival (PFS), secondary endpoints were rate (PFR), objective response (ORR), disease control (DCR) at week 12. Treatment-related...
Breast cancer is now the most common malignant tumor worldwide. About one-fourth of female patients all over world suffer from breast cancer. And about one in six deaths worldwide caused by In terms absolute numbers cases and deaths, China ranks first world. The CACA Guidelines for Holistic Integrative Management Cancer were edited to help improve diagnosis comprehensive treatment China.
Metaplastic breast cancer (MpBC) is an aggressive subtype of all cancer. We aimed to investigate the clinicopathological features, treatments and prognoses MpBC patients.We collected data from patients diagnosed at Tianjin Medical University Cancer Hospital 2010 2017. Kaplan Meier curves Cox regression model were used evaluating clinical outcomes prognostic factors. After removing baseline differences by propensity score matching (PSM), we analyzed prognosis between invasive ductal...
5550 Background: BAT8006 is an antibody-drug conjugate targeting to folate receptor α (FRα). In this phase 1 study, the authors investigated in subjects with solid tumors. Methods: Subjects advance tumor received on day of a 21-day cycle until subject intolerance or disease progression. The study objectives were tolerability, safety, pharmacokinetic characteristics, immunogenicity, preliminary efficacy. Results: As January 5, 2024, 100 Chinese advanced allocated into six cohorts, including...
Abstract HA121-28, a promising multikinase inhibitor, mainly targets rearranged during transfection (RET) fusions and selectively vascular endothelial growth factor receptor-2, receptor, fibroblast receptor 1-3. The safety, pharmacokinetics, efficacy of HA121-28 were assessed in advanced solid tumors (phase 1, ClinicalTrials.gov NCT03994484) RET fusion-positive non-small-cell lung cancer (RET-TKI naive NSCLC, phase 2, NCT05117658). was administered orally doses range from 25 to 800 mg under...
Abstract When the slurry shield tunneling in water rich sandy gravel stratum, it is easy to have problems such as difficult form filter cake and poor stability of excavation face, key factor maintain face. Using finite element software, a three‐dimensional fluid solid coupling model established. The influence parameters (slurry pressure permeability coefficient cake) on pore face during studied. variation laws internal relations parameters, displacement are obtained. results indicate that...
Micheliolide (MCL) is a promising novel compound with broad-spectrum anticancer activity. However, little known regarding its action and mechanism in breast cancer. To explore the potential therapeutic application of MCL as chemosensitivity modulator, this study investigated effects on cisplatin sensitivity cancer underlying mechanisms. In 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cytotoxicity assay xenograft tumor model, enhanced cell line MCF-7 both vitro vivo. Treatment...
Fluzoparib (SHR3162) is a novel, potent poly(ADP-ribose) polymerases (PARP)1, 2 inhibitor that showed anti-tumor activity in xenograft models. We conducted phase I, first-in-human, dose-escalation and expansion (D-Esc D-Ex) trial patients with advanced solid cancer.This was 3+3 I D-Esc 3-level D-Ex at 5 hospitals China. Eligible for had tumors refractory to standard therapies, enrolled ovarian cancer (OC). administered orally once or twice daily (bid) 11 dose levels from 10 400 mg/d....